Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.21 USD | -0.79% | -0.32% | -8.53% |
Financials (USD)
Sales 2024 * | 607M | Sales 2025 * | 620M | Capitalization | 1.95B |
---|---|---|---|---|---|
Net income 2024 * | -470M | Net income 2025 * | -386M | EV / Sales 2024 * | 2.46 x |
Net cash position 2024 * | 456M | Net cash position 2025 * | 310M | EV / Sales 2025 * | 2.64 x |
P/E ratio 2024 * |
-4.11
x | P/E ratio 2025 * |
-4.93
x | Employees | 1,022 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on PTC Therapeutics, Inc.
1 day | -0.79% | ||
1 week | -0.32% | ||
Current month | -13.34% | ||
1 month | -13.34% | ||
3 months | -9.84% | ||
6 months | +10.72% | ||
Current year | -8.53% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 52 | 19-09-30 |
Pierre Gravier
DFI | Director of Finance/CFO | 39 | 23-07-12 |
Ellen Welch
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Steele
BRD | Director/Board Member | 79 | 15-06-14 |
Chairman | 72 | 01-07-31 | |
David Southwell
BRD | Director/Board Member | 63 | 05-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.35% | 16 M€ | -6.73% | ||
0.36% | 0 M€ | 0.00% | - | |
0.25% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 25.21 | -0.79% | 560,544 |
24-04-23 | 25.41 | -2.16% | 754,373 |
24-04-22 | 25.97 | +2.57% | 647,499 |
24-04-19 | 25.32 | +2.55% | 3,931,888 |
24-04-18 | 24.69 | -1.87% | 820,086 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.53% | 1.95B | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- PTCT Stock